Clinical Trials on Lung Cancer Survivors in Japan

Total 1877 results

Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
Hamamatsu University

Completed

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Tokyo University
Shionogi; National Cancer Center Hospital East; Hokkaido University; Fukushima... and other collaborators

Unknown

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

Non-small- Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Takeda

Recruiting

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Daiichi Sankyo Co., Ltd.

Completed

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Cervical Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gastric Cancer (Inoperable and Recurrent)

Japan
Gunma University
J~pharma

Completed

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

Non-Small Cell Lung Cancer

Japan
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shiga University

Completed

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
National Hospital Organization Nagoya Medical Center
Merck Sharp & Dohme LLC; Central Japan Lung Study Group

Active, not recruiting

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Non-squamous Non-small-cell Lung Cancer | Cancer, Lung

Japan
Kobe City General Hospital

Terminated

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Advanced Non-small Cell Lung Cancer

Japan
Kyoto University
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Unknown

Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Non-small-cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Pfizer

Recruiting

Safety and Efficacy of Xalkori ROS1

Non-small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

Japan
Pfizer

Recruiting

Safety and Efficacy of Lorbrena

Non-small Cell Lung Cancer

Japan
R-Pharm

Completed

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Hamamatsu University

Completed

Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer (GEEP)

Non-Small Cell Lung Cancer

Japan
Masahiro Tsuboi
Eli Lilly and Company; Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II | Non-small Cell Lung Cancer Stage IB | Non-small Cell Lung Cancer Stage ⅢA

Japan
Novartis Pharmaceuticals

Completed

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
West Japan Thoracic Oncology Group

Unknown

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

Lung Cancer

Japan
Bristol-Myers Squibb

Completed

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Juntendo University
Baxter Healthcare Corporation

Active, not recruiting

Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia

Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan

Non-Small Cell Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (LIGHT-NING)

Non-Small Cell Lung Cancer

Japan
Gunma University
J~pharma

Completed

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake (angiogenesis)

Non-Small Cell Lung Cancer | Angiogenesis

Japan
Sumitomo Pharma Co., Ltd.

Completed

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Lung Cancer

Japan
Ludwig Institute for Cancer Research
Mie University

Completed

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Stomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer

Japan
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Shiga University
University of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaborators

Unknown

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
Eisai Co., Ltd.

Completed

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Japan
AstraZeneca

Completed

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,

Japan
Osaka University
Ono Pharmaceutical Co. Ltd; Kyowa Kirin Co., Ltd.; Clinical Study Support, Inc.; Fiverings Co., Ltd...

Completed

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Gastric Cancer | Esophageal Cancer | Lung Cancer | Renal Cancer | Oral Cancer

Japan
Bristol-Myers Squibb

Completed

Study of BMS-986012 in Subjects With Small Cell Lung Caner

Small Cell Lung Cancer

Japan
Yokohama City University Medical Center

Completed

Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy (NEIE)

Esophageal Cancer

Japan
Pfizer

Completed

Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
Japan Multinational Trial Organization

Completed

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

Lung Cancer

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan

3

Subscribe